Can Bladder Cancer Be Detected With a Urine Test?

Several urine tests can detect bladder cancer, and some perform well enough that researchers are actively testing whether they can replace the invasive camera procedure (cystoscopy) that remains the standard of care. None has crossed that threshold yet. The current landscape includes traditional urine cytology, protein-based tests, molecular assays that analyze DNA or RNA, and experimental technologies still in early trials. Each has trade-offs between catching cancers and raising false alarms, and the choice of test often depends on whether the goal is initial diagnosis, post-treatment surveillance, or something else entirely.

What Traditional Urine Cytology Can and Cannot Do

Urine cytology is the oldest urine-based approach to bladder cancer detection. A pathologist examines cells shed into the urine under a microscope, looking for the abnormal shapes and features that cancer cells display. The test is highly specific, meaning a positive result is almost always correct. But it misses a lot of cancers, especially low-grade ones. One study found sensitivity as low as 10% for low-grade tumors, climbing to about 51% for high-grade tumors.¹ A more recent analysis using a standardized reporting system showed overall sensitivity reaching about 88%, though that came with a sharp drop in specificity to roughly 27%.²

In practical terms, cytology is most useful when it comes back positive: you can be fairly confident there is cancer. A negative result, though, does not rule cancer out, particularly if the tumor is low-grade. That asymmetry is why cytology alone has never been considered sufficient and why the field has spent decades searching for better urine-based alternatives.

Protein-Based Tests Already on the Market

Two protein biomarker tests have received regulatory clearance and are commercially available: NMP22 BladderChek and BTA stat. Both detect proteins that bladder cancer cells release into urine at higher-than-normal levels.

NMP22 measures nuclear matrix protein 22. A large meta-analysis found the test had overall sensitivity of about 56% and specificity around 88%.³ Its performance varies dramatically by tumor stage: sensitivity for the earliest superficial tumors averaged roughly 14%, but it detected about three-quarters of more advanced tumors that had invaded the muscle wall. A head-to-head comparison with cytology found NMP22 sensitivity of 85% versus 41% for cytology when monitoring for cancer recurrence, and it was roughly eight times more sensitive for low-risk tumors.⁴ Combining both tests pushed overall sensitivity to 91%. A separate meta-analysis that compared NMP22 directly to cytology confirmed that NMP22 picks up more cancers but generates more false positives, and concluded that it cannot currently replace cystoscopy or cytology on its own but works best alongside them.⁵

BTA stat detects a different protein (bladder tumor antigen, a complement factor H-related protein). A meta-analysis comparing BTA stat to cytology found it had higher sensitivity, about 67% versus 43%, but lower specificity.⁶ In other words, BTA stat catches more cancers than cytology does, but it also flags more people who turn out not to have cancer. Urinary tract infections and kidney stones can trigger a positive BTA stat result, which complicates its usefulness in everyday practice.

NMP22 BladderChek also comes in a rapid point-of-care format that works somewhat like a pregnancy test strip, producing results in about 30 minutes. In a large surveillance study, the point-of-care version alone had sensitivity of about 50%, but when combined with cystoscopy, the pair detected 99% of malignancies, including seven of nine high-grade cancers that the camera alone had missed.⁷ That finding is worth pausing on: even an imperfect urine test can catch cancers that cystoscopy misses, because the two methods look for different things.

Molecular and Genetic Urine Tests

A newer generation of tests goes beyond proteins to examine the genetic material shed by tumor cells into urine. These molecular assays tend to outperform both cytology and protein-based tests, though they come at higher cost and require laboratory processing.

Chromosome-Based Testing

UroVysion is a laboratory test that uses fluorescent probes to spot common chromosome abnormalities associated with bladder cancer in urine cells. In a study of over 1,800 paired samples, UroVysion had sensitivity of about 62% versus 29% for cytology, while cytology maintained higher specificity at roughly 97% compared with 90% for UroVysion.⁸ The researchers suggested UroVysion works best as a follow-up test when cytology returns an equivocal result, essentially resolving ambiguous cases rather than replacing the initial screen.

RNA-Based Tests

Cxbladder is a commercially available test that measures the levels of five genes in urine. It comes in three versions tailored to different clinical scenarios. The Detect version, designed for initial evaluation of people with blood in their urine, showed sensitivity of 77% and specificity of 94%. The Triage version, intended to help decide who needs cystoscopy, had sensitivity of 95% with lower specificity of 46%. The Monitor version, for post-treatment surveillance, had sensitivity of 91% and specificity of 39%.⁹ The pattern here is telling: tests designed for triage or monitoring dial up sensitivity (catching nearly every cancer) at the expense of specificity (flagging many people who do not have cancer), because the priority shifts toward not missing disease.

Xpert Bladder Cancer Monitor measures five mRNA targets and is designed specifically for surveillance after treatment. A prospective clinical trial found its sensitivity was 83% compared with 33% for cytology, though both had similar specificity around 97-98%. The test’s negative predictive value hit about 97%, meaning a negative result was very reassuring.¹⁰ Another study reported similar findings, with Xpert achieving 77% sensitivity for predicting malignant results versus 38% for standard cytology, and 100% sensitivity for detecting high-grade tumors.¹¹

Survivin, a protein that suppresses cell death, can also be detected through its RNA in urine. A meta-analysis of head-to-head studies found that testing for survivin mRNA had pooled sensitivity of 86% and specificity of 95%, compared with 42% sensitivity and near-perfect specificity for cytology.¹² The gap was especially wide for lower-grade tumors, which are exactly the cancers that cytology struggles to find.

DNA Methylation Testing

One of the most promising newer approaches looks at chemical modifications to DNA rather than mutations in it. A 2024 study published in JAMA Oncology evaluated a urinary DNA methylation test across more than 1,100 participants. For high-grade or invasive bladder cancer, the test achieved sensitivity of about 89% and specificity of roughly 88%. Its negative predictive value reached about 98%, meaning that among people whose test came back negative, fewer than 3 in 100 actually had high-grade or invasive disease.¹³ For all bladder cancers including low-grade ones, sensitivity dropped to about 78%, which still outperforms most existing options.

A separate approach using urinary tumor DNA showed similarly impressive results in monitoring for recurrence. In a prospective study, patients with positive results had dramatically higher recurrence risk, and among those who tested negative, 96% remained recurrence-free during follow-up.¹⁴

Why Cystoscopy Remains the Gold Standard

Given all these options, you might wonder why anyone still needs a thin camera threaded into the bladder. The answer is that no urine test has simultaneously achieved high enough sensitivity and specificity to stand alone. Each test described above either misses too many cancers or triggers too many false alarms to serve as the sole diagnostic method. Cystoscopy directly visualizes the bladder lining and allows immediate biopsy of suspicious areas, giving it a combination of sensitivity and actionability that urine tests cannot yet match.

That said, cystoscopy is uncomfortable, carries a small risk of infection, and requires clinic visits with specialized equipment. For people who have been treated for non-muscle-invasive bladder cancer, the standard surveillance schedule involves repeated cystoscopies over years, sometimes every three months. The burden on patients is real, and it is the main reason researchers are so motivated to find urine-based alternatives. A multicenter randomized trial called “Replace Cysto” is underway, enrolling 240 participants to test whether alternating urine marker tests with cystoscopy, rather than doing cystoscopy at every visit, improves quality of life without compromising cancer detection.¹⁵

Screening People Without Symptoms

Everything discussed so far applies to people who already have symptoms (most commonly blood in the urine) or a prior cancer diagnosis being monitored. For screening asymptomatic adults, the picture is starkly different. The U.S. Preventive Services Task Force has concluded that the evidence is insufficient to assess the balance of benefits and harms of screening for bladder cancer in asymptomatic adults.¹⁶ No major medical organization recommends routine screening.¹⁷

The reason is partly about the disease’s prevalence in the general population. Among people evaluated for microscopic blood in the urine (already a selected, higher-risk group), only about 1-3% turn out to have bladder cancer. A large study of over 2,100 patients with asymptomatic microscopic blood in their urine found cancer in just 1.2%, all of which were non-muscle-invasive, and no cancers were detected in patients under age 50.¹⁸ When the underlying cancer rate is that low, even a test with 90% specificity would produce far more false positives than true positives, leading to unnecessary cystoscopies, anxiety, and healthcare costs with minimal gain.

What “False Positive” Really Means

False-positive results from urine biomarker tests deserve more nuance than they typically receive. A study that tracked patients whose urine tests were positive but whose initial cystoscopy found no cancer discovered that a meaningful fraction of those “false positives” went on to develop bladder cancer within the follow-up period. Among patients with false-positive results, recurrence rates ranged from about 8-9% for several markers and reached 27% for one marker, compared with 0-5% among patients whose tests were correctly negative.¹⁹ In other words, some “false positives” were actually detecting molecular changes before visible tumors appeared. This phenomenon complicates how we evaluate test performance and suggests that some urine markers may be more sensitive than we give them credit for.

Combining Multiple Tests

Rather than relying on any single urine test, the trend in research is toward combinations. A study comparing the Xpert mRNA test, a urinary metabolomics assay, and cytology found that the metabolomics assay alone had sensitivity of 89% and specificity of 93%, outperforming both Xpert alone and cytology alone. When Xpert and metabolomics results were combined, specificity jumped to 98% and positive predictive value reached 97%, though sensitivity dipped slightly.²⁰ The lesson: pairing tests that are strong in different areas, one catching cancers that the other misses, tends to outperform either test used alone.

Artificial intelligence is accelerating this combinatorial approach. Machine-learning models trained on genomic and protein data from urine samples can weigh multiple biomarkers simultaneously to produce a single probability score, potentially outperforming any individual marker.²¹ These AI-driven models remain in the research phase, but they represent the likely direction of future diagnostics: not a single magic biomarker, but an algorithm integrating many signals from a urine sample.

Experimental Frontiers

Two emerging areas deserve mention, even though they are further from clinical use. The first involves volatile organic compounds, the gaseous molecules that give urine its smell. Tumors alter the body’s metabolism in ways that change the chemical signature of these volatiles. An electronic nose device achieved a cross-validated accuracy of about 88% at distinguishing urine from bladder cancer patients versus healthy controls, with sensitivity of 82% and specificity of 95%.²² An earlier pilot study using a different electronic nose device reported even higher sensitivity, around 93%.²³ A review of the broader field noted that urine-based volatile compound analysis shows considerable promise across multiple cancer types, with bladder cancer being one of the most studied.²⁴ These devices are still small-study territory, but the idea that a machine could sniff a urine sample and flag cancer is no longer science fiction.

The second frontier involves the urinary microbiome, the community of bacteria naturally present in urine. Research has found that bladder cancer patients harbor a different bacterial profile than healthy people. In one study, certain bacterial species like Actinobaculum schaalii and Porphyromonas somerae were significantly more abundant in cancer patients, while Lactobacillus and Streptococcus species were diminished.²⁵ Other research has suggested that shifts in the urinary microbiome may even track with tumor progression from non-invasive to invasive stages.²⁶ Whether microbiome signatures will eventually become a useful diagnostic tool, perhaps as one more input into a multi-marker algorithm, remains an open question. The research is early, but the consistent finding of distinct bacterial profiles in cancer patients is intriguing.

Practical Takeaways if You Are Being Evaluated

If your doctor orders a urine test in the context of bladder cancer, the most important thing to understand is what a negative result means for your specific test. A negative result on a test with a high negative predictive value (like the DNA methylation test or Xpert) is genuinely reassuring: it substantially lowers the chance you have high-grade or invasive cancer. A negative result on standard cytology is far less reassuring, because cytology misses too many cancers, especially low-grade ones.

A positive result on any urine test will almost always lead to cystoscopy for confirmation. No urologist will treat you based on a urine result alone. The value of urine testing, at least right now, lies in triaging who needs cystoscopy urgently, who can safely delay it, and how frequently it needs to be repeated during long-term surveillance. For the millions of people who see blood in their urine each year and need evaluation, a urine test that reliably sorts high-risk from low-risk patients saves a lot of unnecessary procedures. For the hundreds of thousands undergoing cancer surveillance, a urine test that lets some cystoscopies be replaced or spaced out makes a real difference in daily life. Neither of those roles requires a perfect test. They just require a test good enough to change the clinical math, and several are now getting close.